
 <div id="CLN5_desc" class="disease_desc" style="width: 77%;">
         <h2  class="dis_title"><IMG class="dis_dna" src="img/dna_vert_med.png" align="middle"/>CLN5</h2>
<h3 class="dis_subtitle">Ceroid lipofuscinosis, neuronal, 5</h3>

          <div class="container dis_desc2"> 

  <h4  style="color: #000000;">Genes associated with this disease:</h4>
<li>  <a href="exturl.html?gene=CLN5&name=Ceroid-lipofuscinosis%20neuronal%20protein%205%20Precursor&ensemb=ENSG00000102805&disease=CLN5&omim=608102&exturl=http://www.ucl.ac.uk/ncl/CLN5mutationtable.htm&extsrc=http://www.ucl.ac.uk/ncl/mutation.shtml&extsrctitle=NCL%20Mutation%20and%20Patient%20Database&curator=Sara%20Mole&ncbi=1203">CLN5</a> </li>
</div>
<br/>
<div class="container dis_desc2">

Ceroid lipofuscinosis, neuronal, 5 (CLN5) was originally described as the 'Finnish variant of late-infantile NCL' (Finnish vLINCL). With the identification of molecular defect, CLN5 now refers to CLN caused by mutation in the CLN5 gene, regardless of the age at onset.

<br/><br/>

Typical CLN5, Finnish vLINCL form, first presents at the age of 4 to 7 years usually with motor clumsiness and progressive mental deterioration. Visual failure and myoclonic seizures appear later. Most patients become non-ambulatory during the second decade with death between 13 and 30 years of age. MRI studies show signs of cortical atrophy. Three atypical phenotypes can also be recognized: juvenile, adult and infantile CLN5 disease.

<br/><br/>

The product of CLN5 gene is a soluble lysosomal glycoprotein, but the pathogenetic mechanisms leading to neuronal death and accumulation of cytosomes with curvilear profiles, and/or fingerprint profiles are mostly unknown. The accumulating substance is subunit c of mitochondrial ATP synthase. 

<br/><br/>

See review: Kousi et al. Human mutation 2011:33:42-63

  <br>
  </div>

<br/>

<div class="container dis_desc2">

<h4  style="color: #000000;">Selected References:</h4>

<li> 
Savukoski M, Klockars T, Holmberg V, Santavuori P, Lander ES, Peltonen L. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9662406" target="_blank">CLN5, a novel gene encoding a putative transmembrane protein mutated in Finnish variant late infantile neuronal ceroid lipofuscinosis.</a> Nat Genet. 1998 Jul;19(3):286-8.

<br/><br/>

<li> Kousi M, Lehesjoki AE, Mole SE. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21990111" target="_blank">Update of the mutation spectrum and clinical correlations of over 360 mutations in eight genes that underlie the neuronal ceroid lipofuscinoses.</a> Hum Mutat. 2012 Jan;33(1):42-63. Review

<br/><br/>

      <span class="" style="float: right;"><b><a href="diseases.html"><img src="img/disease.png" height="25" width="25" style="position: relative; top: -4;left: -4;"></a></b></span>
</div>

<br/>
<div class="container dis_desc2">

  <h4  style="color: #000000;">More information:</h4>
    <li><a href="pub.html?disease=CLN5" target="_blank">CLN5 Publications</a>
    <li> <a href="http://omim.org/entry/256731" target="_blank">Omim disease entry</a>

  <br/>

      <span class="" style="float: right;"><b><a href="diseases.html"><img src="img/disease.png" height="25" width="25" style="position: relative; top: -4;left: -4;"></a></b></span>
</div>
   
     <br/>
    </div>
  </div>